Filtered By:
Cancer: Skin Cancer
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 36609 results found since Jan 2013.
Protein kinase signaling networks driven by oncogenic Gq/11 in uveal melanoma identified by phosphoproteomic and bioinformatic analyses
Mol Cell Proteomics. 2023 Sep 18:100649. doi: 10.1016/j.mcpro.2023.100649. Online ahead of print.ABSTRACTMetastatic uveal melanoma (mUM) patients typically survive only 2-3 years because effective therapy does not yet exist. Here, to facilitate the discovery of therapeutic targets in UM, we have identified protein kinase signaling mechanisms elicited by the drivers in 90% of UM tumors: mutant constitutively active G protein α-subunits encoded by GNAQ (Gq) or GNA11 (G11). We used the highly specific Gq/11 inhibitor FR900359 (FR) to elucidate signaling networks that drive proliferation, metabolic reprogramming, and dediffer...
Source: Molecular and Cellular Proteomics : MCP - September 20, 2023 Category: Molecular Biology Authors: Michael D Onken Petra Erdmann-Gilmore Qiang Zhang Kisan Thapa Emily King Kevin M Kaltenbronn Sarah E Noda Carol M Makepeace Dennis Goldfarb Özgün Babur R Reid Townsend Kendall J Blumer Source Type: research
Treatment management for < em > BRAF < /em > -mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
CONCLUSIONS: BRAFmut melanoma patients who developed DM upon upfront adjuvant therapy achieve favorable tumor control and prolonged PFS after switching treatment modalities in the first-line setting of stage IV disease. Patients with locoregional recurrence benefit from complete resection of recurrence followed by a second adjuvant treatment with TT.PMID:37730278 | DOI:10.1136/jitc-2023-007630
Source: Cancer Control - September 20, 2023 Category: Cancer & Oncology Authors: Maximilian Haist Henner Stege Friederike Rogall Yuqi Tan Imke von Wasielewski Kai Christian Klespe Friedegund Meier Peter Mohr Katharina C K ähler Michael Weichenthal Axel Hauschild Dirk Schadendorf Selma Ugurel Georg Lodde Lisa Zimmer Ralf Gutzmer Dirk Source Type: research
Twenty years of research in melanoma therapy-From "nothing works" to cures: A personal account
Pigment Cell Melanoma Res. 2023 Sep 19. doi: 10.1111/pcmr.13133. Online ahead of print.NO ABSTRACTPMID:37726985 | DOI:10.1111/pcmr.13133
Source: Pigment Cell and Melanoma Research - September 20, 2023 Category: Cytology Authors: Meenhard Herlyn Jessie Villanueva Source Type: research
MEK inhibition induces expression of differentiation marker Keratin 10 in human keratinocytes
Pathol Res Pract. 2023 Sep 2;250:154788. doi: 10.1016/j.prp.2023.154788. Online ahead of print.ABSTRACTBRAF mutant metastatic melanoma was regularly treated in the past with a BRAF inhibitor (BRAFi) alone or in combination with inhibitors of the mitogen-activated protein kinase kinase (MEKi), which is still a common treatment. This combination therapy strongly reduced the occurrence of keratoacanthomas and squamous cell carcinoma, which was frequently seen when BRAFi was used as monotherapy. Here we addressed the question whether MEK inhibition counteracts squamous cell carcinoma development in part by promoting keratinocy...
Source: Pathology, Research and Practice - September 20, 2023 Category: Pathology Authors: F Karras M Bonsack S Seifert L Friedrich M Kunz Source Type: research
PMN-incorporated multifunctional chitosan hydrogel for postoperative synergistic photothermal melanoma therapy and skin regeneration
In this study, carboxymethyl chitosan, oxidized fucoidan and polyphenol-metal nanoparticle (PMN) of tannic acid capped gold nanoparticles were used to fabricate multifunctional nanocomposite hydrogels through Schiff base reaction. The prepared hydrogel demonstrated outstanding photothermal effect, and the controlled high temperature will rapidly kill melanoma cells as well as bacteria within 10 min. Good injectability, self-healing and adhesion combined with high reactive oxygen species (ROS) scavenging capacity, hemostasis and biocompatibility made this hydrogel platform perfect for the treatment of mice melanoma resectio...
Source: International Journal of Biological Macromolecules - September 20, 2023 Category: Biochemistry Authors: Rong Chang Donghui Zhao Chen Zhang Kaiyue Liu Yuanmeng He Fangxia Guan Minghao Yao Source Type: research
Neuroendocrine carcinoma of the cervix: About a rare case and literature review
CONCLUSION: To improve the survival of patients with large-cell neuroendocrine carcinomas of the uterine cervix, it is imperative to conduct multicenter clinical trials aimed at defining an effective, standardized treatment.PMID:37729821 | DOI:10.1016/j.ijscr.2023.108835
Source: Hand Surgery - September 20, 2023 Category: Surgery Authors: Imane El Abbassi S O Tanguara Y Bencherifi M Ennachit M Benhessou M El Kerroumi Source Type: research
MEK inhibition induces expression of differentiation marker Keratin 10 in human keratinocytes
Pathol Res Pract. 2023 Sep 2;250:154788. doi: 10.1016/j.prp.2023.154788. Online ahead of print.ABSTRACTBRAF mutant metastatic melanoma was regularly treated in the past with a BRAF inhibitor (BRAFi) alone or in combination with inhibitors of the mitogen-activated protein kinase kinase (MEKi), which is still a common treatment. This combination therapy strongly reduced the occurrence of keratoacanthomas and squamous cell carcinoma, which was frequently seen when BRAFi was used as monotherapy. Here we addressed the question whether MEK inhibition counteracts squamous cell carcinoma development in part by promoting keratinocy...
Source: Cell Research - September 20, 2023 Category: Cytology Authors: F Karras M Bonsack S Seifert L Friedrich M Kunz Source Type: research
Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma
Cancer Res. 2023 Sep 20. doi: 10.1158/0008-5472.CAN-23-0485. Online ahead of print.ABSTRACTMetastatic melanoma is either intrinsically resistant or rapidly acquires resistance to targeted therapy treatments, such as MAPK inhibitors. A leading cause of resistance to targeted therapy is a dynamic transition of melanoma cells from a proliferative to a highly invasive state, a phenomenon called phenotype switching. Mechanisms regulating phenotype switching represent potential targets for improving treatment of melanoma patients. Using a drug screen targeting chromatin regulators in patient-derived 3D MAPK inhibitor-resistant m...
Source: Cell Research - September 20, 2023 Category: Cytology Authors: Lorenza P Ferretti Flurina B öhi Deena M Leslie Pedrioli Phil F Cheng Elena Ferrari Petra Baumgaertner Abdiel Alvarado-Diaz Federica Sella Alessandra Cereghetti Patrick Turko Roni H Wright Katrien De Bock Daniel E Speiser Roberto Ferrari Mitchell P Leves Source Type: research
Targeted therapy and immunotherapy for orbital and periorbital tumors: a major review
This article will focus on recent updates in the application of available targeted and immunotherapy for managing orbital and periorbital tumors and tumor-like conditions, which include cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, cutaneous melanoma, Merkel cell carcinoma, sebaceous gland carcinoma, solitary fibrous tumor, dermatofibrosarcoma protuberans, orbital meningioma, neurofibromatosis, Langerhans cell histiocytosis, ocular adnexal lymphoma, orbital lymphatic malformation, and adenoid cystic carcinoma.PMID:37728602 | DOI:10.1080/01676830.2023.2256848
Source: Orbit - September 20, 2023 Category: Opthalmology Authors: Emmanuel Lee Boniao Richard C Allen Gangadhara Sundar Source Type: research
Downregulated BIRC5 inhibits proliferation and metastasis of melanoma through the β-catenin/HIF-1α/VEGF/MMPs pathway
CONCLUSION: Our findings revealed that ZWZ-3 could downregulate BIRC5 and inhibit melanoma proliferation and metastasis through the β-catenin/HIF-1α/VEGF/MMPs pathway. Therefore, BIRC5 represents a promising therapeutic target for the treatment of melanoma.PMID:37728702 | DOI:10.1007/s00432-023-05425-3
Source: Cell Research - September 20, 2023 Category: Cytology Authors: Qingqing He Yijing He Changqiang Li Jianv Wang Tong Xia Xia Xiong Jixiang Xu Li Liu Source Type: research
Twenty years of research in melanoma therapy-From "nothing works" to cures: A personal account
Pigment Cell Melanoma Res. 2023 Sep 19. doi: 10.1111/pcmr.13133. Online ahead of print.NO ABSTRACTPMID:37726985 | DOI:10.1111/pcmr.13133
Source: Cell Research - September 20, 2023 Category: Cytology Authors: Meenhard Herlyn Jessie Villanueva Source Type: research
RT-qPCR Analysis of LAMP3 (CD208) Gene Expression in Oral Lichen Planus and Oral Squamous Cell Carcinoma
CONCLUSIONS: According to the findings of this study, it can be concluded that the expression of the LAMP3 gene in SCC lesions is higher than in healthy tissue. Hence, LAMP3 gene expression can be used as a diagnostic biomarker.PMID:37724152 | PMC:PMC10505466 | DOI:10.52547/rbmb.12.1.36
Source: Mol Biol Cell - September 19, 2023 Category: Molecular Biology Authors: Farnaz Mohajertehran Nooshin Mohtasham Mojtaba Ahmadi Mehdi Shahabinejad Maryam Mohammadi Source Type: research
Interactive effects of CDKN2B-AS1 gene polymorphism and habitual risk factors on oral cancer
J Cell Mol Med. 2023 Sep 19. doi: 10.1111/jcmm.17966. Online ahead of print.ABSTRACTOral squamous cell carcinoma (OSCC) is a common malignant disease associated with a high mortality rate and heterogeneous disease aetiology. Cyclin dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1), is a long noncoding RNA that has been shown to act as a scaffold, sponge, or signal hub to promote carcinogenesis. Here, we attempted to assess the effect of CDKN2B-AS1 single-nucleotide polymorphisms (SNPs) on the susceptibility to OSCC. Five CDKN2B-AS1 SNPs, including rs564398, rs1333048, rs1537373, rs2151280 and rs8181047, were analy...
Source: Molecular Medicine - September 19, 2023 Category: Molecular Biology Authors: Jung-Chun Yeh Yi-Tzu Chen Ying-Erh Chou Shih-Chi Su Lun-Ching Chang Yen-Lin Chen Chiao-Wen Lin Shun-Fa Yang Source Type: research
